Literature DB >> 9354664

A coagulation factor IX-deficient mouse model for human hemophilia B.

H F Lin1, N Maeda, O Smithies, D L Straight, D W Stafford.   

Abstract

Coagulation factor IX deficiency causes hemophilia B in humans. We have used gene targeting to develop a coagulation factor IX-deficient (factor IX-knockout) mouse strain. Mouse embryonic stem (ES) cells were targeted by a socket-containing vector that replaces the promoter through exon 3 of the factor IX gene by neoDeltaHPRT, which is a functional neo gene plus a partially deleted hypoxanthine phosphoribosyl transferase minigene. Chimeric mice generated using these socket-containing ES cells transmitted the targeted factor IX gene to their female offspring. Male offspring from these females were characterized and shown to exhibit a phenotype similar to hemophilia B. This factor IX-deficient mouse strain will be useful for studying gene therapy methods and structure-function relationships of recombinant factor IX proteins in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354664

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  90 in total

Review 1.  Gene therapy for the hemophilias.

Authors:  M A Kay; K High
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

Review 2.  Adeno-associated virus vectors and hematology.

Authors:  D W Russell; M A Kay
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

Review 3.  Adeno-associated virus-mediated gene transfer for hemophilia B.

Authors:  Katherine A High
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

Review 4.  Wound healing in hemophilia B mice and low tissue factor mice.

Authors:  Dougald M Monroe; Nigel Mackman; Maureane Hoffman
Journal:  Thromb Res       Date:  2010-02-19       Impact factor: 3.944

Review 5.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Nat Rev Genet       Date:  2011-05       Impact factor: 53.242

6.  Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.

Authors:  Mario Cooper; Sushrusha Nayak; Brad E Hoffman; Cox Terhorst; Ou Cao; Roland W Herzog
Journal:  Hum Gene Ther       Date:  2009-07       Impact factor: 5.695

Review 7.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

8.  Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice.

Authors:  Dheeraj Verma; Babak Moghimi; Paul A LoDuca; Harminder D Singh; Brad E Hoffman; Roland W Herzog; Henry Daniell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

9.  The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.

Authors:  Giulia Pavani; Lacramioara Ivanciu; Armida Faella; Oscar A Marcos-Contreras; Paris Margaritis
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

10.  Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow.

Authors:  Frauke Swieringa; Marijke J E Kuijpers; Moniek M E Lamers; Paola E J van der Meijden; Johan W M Heemskerk
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.